CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product  Candidate REHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary  recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal fill ...